Crescel LLC's Landmark Publication: A Major Step for Non-Pharmaceutical Rosacea Treatment

In a significant breakthrough for dermatological health, Crescel LLC, a Florida-based science and technology company, has announced the publication of a pioneering clinical study in the Journal of Cosmetic Dermatology. This peer-reviewed research spotlights the efficacy of Crescel's biobotanical Skin Renewal Cream, demonstrating statistically significant results in treating rosacea compared to the leading prescription medication.

Rosacea, a chronic inflammatory skin condition affecting over 400 million people worldwide, poses a significant healthcare challenge. The clinical trial, which was randomized, double-blind, and controlled, indicated that Crescel's technology reduced facial redness by 54% versus just 23% achieved with the current standard of care. Furthermore, the biobotanical cream resulted in a remarkable 74% reduction in inflammatory lesions compared to the 17% reduction from prescription treatments. These findings highlight not only the potential for improved health outcomes but also an opportunity for more affordable healthcare solutions.

Peter J. Passalacqua, Jr., the Co-Founder and CEO of Crescel, emphasized the importance of this publication. He commented, "Healthcare systems around the world are searching for innovative solutions that improve outcomes while reducing long-term costs. Our peer-reviewed publication validates years of scientific research and reinforces our belief that breakthrough biobotanical technologies can play an increasingly important role in the future of healthcare."

This study marks a milestone for Crescel, as it offers evidence that botanical-based treatments can compete effectively with conventional pharmaceutical approaches, indicating a shift towards non-pharmaceutical options in healthcare. The excellent safety profile of the Skin Renewal Cream, with no reported adverse effects, further broadens its appeal.

Additionally, Dr. Roberta Shapiro, an Assistant Clinical Professor at Columbia University Medical Center and Chief Medical Officer of Crescel, lauded the study. "This is one of the most exciting medical advancements I have seen in my 30 years of practicing rehabilitation medicine. Crescel's healing capabilities are exceptional, and this innovative technology has the potential to improve care while expanding access to safe, effective, non-pharmaceutical options."

Crescel's commitment to enhancing patient care goes beyond addressing rosacea, as the company has recorded promising real-world outcomes across various high-cost skin conditions. The results from the clinical trial serve as a beacon for those seeking alternatives to traditional pharmaceutical treatments, fostering hope for many individuals experiencing the debilitating effects of rosacea.

The complete study, titled "Efficacy, Tolerance, and Safety of a Novel Botanical Anti-Inflammatory Moisturizer in Rosacea: Results From a Double-Blinded, Randomized Controlled Trial," is accessible through PubMed and reflects extensive research into innovative care.

For more information on Crescel and their groundbreaking work in biobotanical treatments, visit their website at www.crescel.com. This landmark study not only sets a new standard in skincare but also symbolizes a transformative step towards more accessible and effective healthcare solutions for conditions previously reliant on pharmaceuticals.